7 Min Read ZURICH (Reuters) - U.S. regulators have recommended pausing the use of Johnson & Johnson’s COVID-19 vaccine, as they investigate rare blood clotting in six women. Syringes are prepared to administer the AstraZeneca coronavirus disease (COVID-19) vaccine at a new mass vaccination centre in WiZink sports arena in Madrid, Spain, April 9, 2021. REUTERS/Sergio Perez J&J also said it was stopping the rollout of its vaccine in Europe. The move comes after Europe’s drug regulator earlier this month said it had found a possible link between AstraZeneca’s COVID-19 vaccine and very rare...